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1. General introduction 
 
PATHOLOGY OF SOCIAL ANXIETY 
DISORDER 
Social anxiety disorder (SAD; also known as social 
phobia) is classified in the Diagnostic and Statistical 
Manual of Mental Disorders IV (DSM-IV) 
[American Psychiatric Association, 1994]. People 
with social anxiety disorder fear and avoid the 
scrutiny of others. The concern in such situations is 
that the individual will say or do something that will 
result in embarrassment or humiliation. These 
concerns can be so pronounced that the individual 
shuns most interpersonal encounters, or endures 
such situations only with intense discomfort. Once 
largely neglected by the medical community, social 
anxiety disorder came to the attention of the general 
medical community a decade ago [Stein, 1996], and 
is now garnering increased attention and recognition 
as a widespread, impairing, but treatable condition 
[Schneier, 2006]. SAD is one of the most prevalent 
psychiatric disorders in developed and developing 
countries [Stein et al., 2010b], typically beginning in 
childhood or adolescence. If left untreated, SAD is 
associated with the subsequent development of 
major depression, substance abuse and other mental 
health problems. Thus, SAD can be associated with 
functional disability (including social and 
occupational impairment), low health-related quality 
of life and economic burden [Stein et al., 2005b; 
Wang et al., 2005; Sareen et al., 2006]. 
Individuals with social anxiety disorder are 
typically shy when meeting new people, quiet in 
groups, and withdrawn in unfamiliar social settings. 
When they interact with others, they might or might 
not show overt evidence of discomfort (e.g. blushing, 
not making eye contact), but invariably experience 
intense emotional or physical symptoms, or both 
(e.g. fear, heart racing, sweating, trembling, trouble 
concentrating). They crave the company of others, 
but shun social situations for fear of being found out 
as unlikable, stupid, or boring. Accordingly, they 
avoid speaking in public, expressing opinions, or 
even fraternizing with peers; in some situations, this 
can lead to such individuals being mistakenly 
labeled as snobs. The disorder has two subtypes: 
generalized and non-generalized SAD. In 
generalized SAD, distressing fears are experienced 
in most social situations (e.g. in conversations, 
meetings, parties, performances, and other 
interactions). In non-generalized or circumscribed 
SAD, fears are limited to one or a few social 
situations. 
 
 
RECOMMENDED TREATMENT FOR 
SOCIAL ANXIETY DISORDER 
Pharmacotherapy and psychotherapy have been 
recommended as the first-line treatments for SAD 
[Bandelow et al., 2008; Stein et al., 2010a; Blanco et 
al., 2013]. In terms of pharmacotherapy, a growing 
database of randomized, controlled trials 
demonstrates that selective serotonin reuptake 
inhibitors (SSRIs) are effective and well tolerated 
[Blanco et al., 2013]. In psychotherapy, cognitive 
behavioral therapy (CBT) has consistently been 
shown to be effective in randomized, controlled 
trials [Hofmann & Smits, 2008]. While no clear 
evidence has shown that the combination of SSRIs 
and CBT is more effective than single-modality 
treatment [Blomhoff et al., 2001; Davidson et al., 
2004], CBT has a number of potential advantages 
over pharmacotherapy in the treatment of anxiety 
disorder: longer effects, fewer adverse effects, 
smaller relapse rates, and greater acceptability 
[Gelernter et al., 1991; Heimberg et al., 1998; 
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Hofmann et 1998]. Pharmacotherapy has 
disadvantages such as more side effects and higher 
rates of relapse with the discontinuation of 
medication [Lepola et al., 2004; Liebowitz et al., 
2005a & b]. 
  Despite CBT has a number of potential 
advantages over pharmacotherapy, previous reports 
about the effectiveness of CBT mostly came from 
Europe and North America, and CBT models and 
treatment components were developed in Western 
cultures with theoretical orientations typically 
constrained by Western conceptualizations of SAD. 
No study has tested the effectiveness of CBT for a 
Japanese patient with SAD, and therefore, CBT for 
SAD has not been approved in Japan as of 2012. It 
is necessary to investigate whether individual CBT 
can achieve favorable treatment outcomes in 
Japanese patients with SAD. 
As for the choice of treatment options, the first  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
line of pharmacotherapy involves the administration 
of a SSRI in many countries. Although a significant 
proportion of patients with SAD fail to respond to 
the initial SSRI administration [Stein & Stein, 
2008]; however, there is no standard approach to 
their management. On the whole, conventional 
second-line treatment is based on the clinician’s own 
judgment. Clearly, it is of increasing importance to 
consider therapeutic alternatives for patients with 
SAD who demonstrate resistance to SSRIs. 
 
AIM 
The aims of this study were as follows: 
1) We translated and standardized the CBT 
treatment manual in order to allow for Japanese 
therapists to use CBT manual, which was 
originally developed in Western countries. 
2) We carried out a single-arm clinical trial to 
evaluate the clinical feasibility of CBT for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of the 
cognitive behavioral therapy 
program over 16 weekly 
sessions. Additional customization 
of sessions are allowed at any 
stage of the CBT program. 
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Japanese SAD patients. 
3) We designed and started a randomized controlled 
trial to evaluate the clinical effectiveness of CBT 
administered concomitantly with conventional 
treatment for patients with SSRI-resistant SAD. 
 
 
2. Standardize the treatment manual 
 
Because the CBT model developed by Clark and 
Wells [Clark & Wells, 1995] has shown excellent 
treatment outcomes [Mörtberg et al., 2007; Stangier 
et al., 2003 & 2011; Clark et al., 2003 & 2006], we 
translated and standardized the CBT treatment 
manual based on the model of Clark and Wells 
(1995). 
The main steps in treatment were as follows: (1) 
developing an individualized version of the 
cognitive-behavioral model of SAD; (2) conducting 
role play based behavioral experiments with and 
without safety behaviors; (3) restructuring distorted 
self-imagery using videotape feedback; (4) 
practicing external focus and shifting attention; (5) 
behavioral experiments to test negative beliefs; (6) 
modifying problematic pre- and post-event 
processing; (7) discussing the differences between 
self-beliefs and other people’s beliefs (reflected in 
survey results); (8) dealing with the remaining 
assumptions (schema work); (9) rescripting early 
memories linked to negative images in social 
situations; and (10) preventing relapse (Figure 1 
presents an overview). For details, please read our 
treatment manual in Japanese (APPENDIX 1). 
 
 
 
 
 
3. A preliminary study of individual cognitive 
behavioral therapy for social anxiety 
disorder in Japanese clinical settings: a 
single-arm, uncontrolled trial 
 
3-1. BACKGROUND 
CBT was introduced into Japanese psychiatry in 
the late 1980s, and awareness of the effectiveness of 
CBT has spread, not only among professionals and 
academics but also among the general public. In 
April 2010, CBT for mood disorders (beyond that 
for anxiety disorders) began to be covered by 
Japan’s national health insurance system. 
Nevertheless, a recent nationwide survey in Japan 
demonstrated that only 28% of medical facilities 
reported being able to conduct any form of 
psychotherapy satisfactorily [Ono et al., 2011] 
because of the limited availability of specialized 
practitioners. Only SSRIs (fluvoxamine and 
paroxetine) have been established as first-line 
treatments for Japanese patients with SAD as of 
2012. It is therefore necessary to investigate whether 
CBT can achieve favorable treatment outcomes in 
Japanese SAD patients. 
Previous reports about the effectiveness of CBT 
mostly came from Europe and North America, and 
CBT models and treatment components were 
developed in Western cultures with theoretical 
orientations typically constrained by Western 
conceptualizations of SAD. Cultural factors may be 
especially relevant to SAD pathology. For example, 
taijin-kyofu-sho (in Japanese, taijin means 
“interpersonal,” kyofu means “fear,” and sho means 
“syndrome”), which is listed in the appendix to 
DSM-IV, is said to be a culture-bound syndrome 
that is unique to East Asia. Although fear of 
interpersonal relations has been considered a 
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culture-bound syndrome [Prince & Tcheng-Laroche, 
1987; Russell, 1989; Kleinknecht etal., 1997], it can 
also be classified under existing categories in the 
DSM-IV-TR [Suzuki et al., 2003; Choy et al., 2008; 
Hofmann et al., 2010]. The notion that fear of 
interpersonal relations is purely a culture-bound 
syndrome does not always hold true. Despite 
differences between the conceptualizations of SAD 
and taijin-kyofu-sho, patients suffering from SAD in 
different parts of the world share many features in 
common, and similar assessments and treatments 
have been utilized across the world [Stein, 2009]. 
Only Chen and colleagues [Chen et al., 2007 & 
2010; Watanabe et al., 2010] showed that group 
CBT can bring about a similar degree of symptom 
reduction for Japanese patients as for Western 
patients with SAD. However, no study has tested the 
effectiveness of individual CBT for SAD in Japan. It 
is necessary to investigate whether individual CBT 
can achieve favorable treatment outcomes in 
Japanese patients with SAD, because some recent 
studies from Europe and North America have 
suggested that individual CBT is more effective than 
group CBT [Mörtberg et al., 2007; Stangier et al., 
2003]. In addition, SAD has commonly been found 
to be highly comorbid with other Axis-I disorders, 
such as depression, bipolar disorder, and other 
anxiety disorders. Therefore, it is also important to 
understand how comorbidity and other clinical 
demographics affect treatment outcomes for SAD in 
clinical settings. 
Thus, the purposes of this study are to report the 
preliminary outcomes of an individual CBT program 
for SAD in Japanese clinical settings and to examine 
the baseline predictors of the short-term outcomes 
associated with receiving CBT. The hypothesis is 
that individual CBT will be associated with 
decreased SAD severity in Japanese clinical settings 
and achieve comparable effectiveness to 
applications reported in Western settings. 
 
3-2. METHODS 
Study design 
This study was conducted as a single-arm, open trial 
to report the preliminary outcomes and the 
feasibility of a CBT intervention for SAD in 
Japanese clinical settings. Because this study was 
the first trial to employ an individual CBT 
intervention for SAD in East Asia (particularly in 
Japan), a single-arm trial examining baseline 
predictors rather than an efficacy trial is an 
appropriate design [Mohr et al., 2009]. 
After enrolling in the study, patients were placed 
on a 2-week waiting period to establish the baseline 
stability of their symptoms. At the end of the 
waiting period, the patients received a CBT 
intervention for 14 weeks. Concomitant medications 
were permitted if the dose had been stable for at 
least 4 weeks prior to study entry and remained 
stable throughout the study. Assessments were 
conducted at baseline (week 0), pre-CBT (before 
session 1/week 2), mid-CBT (after session 7/week 
9), and post-CBT (after session 14/week 16) time 
points. 
This study was conducted at the psychiatric 
outpatient section at Chiba University Hospital and 
was performed in compliance with the Helsinki 
Declaration. The study protocol was approved by 
the Ethics Committee of the Chiba University 
Graduate School of Medicine (Reference number: 
1216) and was registered in the national UMIN 
Clinical Trials Registry (ID: UMIN000005897). 
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Participants 
The criteria for inclusion in this study were a 
primary diagnosis of SAD according to the DSM-IV, 
age of 18–65 years, and at least moderately severe 
SAD (on the basis of a Liebowitz Social Anxiety 
Scale [LSAS] score ≥ 50) [Liebowitz ,1987; Raj, 
2001]. Because Sugawara et al. (2012) reported that 
the mean total LSAS score was 42.4 (average SD = 
27.5) in healthy Japanese community-dwelling 
subjects (N = 929) [Sugawaraet al., 2012], we set a 
cutoff score of 50 on the LSAS for screening 
patients as suffering from moderate–severe 
symptoms of SAD. So that the study population 
would reflect routine clinical practice, comorbid 
diagnoses were permitted if clearly secondary (i.e., 
the SAD symptoms were both the most severe and 
the most impairing). 
The exclusion criteria were psychosis, pervasive 
developmental disorders/mental retardation, autism 
spectrum disorders (Autism Spectrum Quotient ≥ 
32) [Baron-Cohen, 2001], current high risk of 
suicide, substance abuse or dependence in the past 6 
months, antisocial personality disorder, unstable 
medical condition, pregnancy, or lactation. 
All patients were evaluated by a psychiatrist using 
the Structured Clinical Interview for Axis I 
Disorders (SCID-I) [First, 1997a]. All patients were 
also screened for autism spectrum disorder with the 
Autism Spectrum Quotient [Baron-Cohen, 2001] 
and the avoidant personality disorder section of the 
SCID–II [First, 1997b], because those measures 
show some overlap with social-anxiety features and 
cannot be screened using SCID-I. Treatment history 
was confirmed by the prescribing clinician and by 
chart review. 
 
Interventions 
The CBT intervention was conducted in 14 weekly 
90-minute sessions. Because the CBT model 
developed by Clark and Wells [Clark & Wells, 1995] 
has shown excellent treatment outcomes [Mörtberg 
et al., 2007; Stangier et al., 2003; Clark et al., 2003; 
Clark et al., 2006; Stangier et al., 2011], our CBT 
program is based on the model of Clark and Wells. 
The main steps in treatment were as follows: (a) 
developing an individualized version of the 
cognitive-behavioral model of SAD; (b) conducting 
role play–based behavioral experiments with and 
without safety behaviors; (c) restructuring distorted 
self-imagery using videotape feedback; (d) 
practicing external focus and shifting attention; (e) 
behavioral experiments to test negative beliefs; (f) 
modifying problematic pre- and post-event 
processing; (g) discussing the differences between 
self-beliefs and other people’s beliefs (reflected in 
survey results); (h) dealing with the remaining 
assumptions (schema work); (i) rescripting early 
memories linked to negative images in social 
situations; and (g) preventing relapse. Homework 
was assigned after every session. 
 
Therapist and quality control 
The CBT intervention was delivered by 6 therapists 
(3 clinical psychologists, 1 nurse, 1 psychiatrist, and 
1 psychiatric social worker) who were experienced 
in the use of CBT for anxiety disorders and had 
completed the CBT training program at Chiba 
University (Chiba Improving Access for 
Psychological Therapies project). To check 
adherence to the protocol and assist with planning 
future sessions for each treatment, all therapists 
attended weekly group supervision sessions with 
other therapists and supervision sessions with a 
senior supervisor. The senior supervisor also 
checked the quality of their CBT on the basis of the 
Cognitive Therapy Scale-Revised [Blackburn et al., 
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2001]. 
 
Outcomes 
The primary outcome measure was self-reported 
symptoms of social anxiety, as measured on the 
LSAS [Liebowitz ,1987], which is the most 
frequently used scale for the assessment of SAD. To 
assure comparability with previous CBT studies 
using the model of Clark and Wells, patients also 
completed additional self-report measures of SAD 
severity: the Social Phobia Scale/Social Interaction 
Anxiety Scale (SPS/SIAS) [Mattick et al., 1998], the 
Fear of Negative Evaluation Scale (FNE) [Watson & 
Friend, 1969], and the Fear Questionnaire – Social 
Phobia subscale (FQ-SP) [Marks & Mathews, 1979]. 
Good reliability and validity of the Japanese 
versions have been reported for the LSAS, SPS, 
SIAS, and FNE [Asakura et al., 2002; Kanai et al., 
2004; Ishikawa et al., 1992]. 
 
Statistical analysis 
The analysis was by intention-to-treat, and the last 
obtained data points for non-completers (because of 
adverse events, lack of compliance, etc.) were 
carried forward until the endpoint assessment. All 
statistical tests were two-tailed, and an α of .05 was 
employed. All of the data were analyzed using IBM 
SPSS Statistics for Windows, Version 20.0 (IBM, 
Armonk, New York, USA). 
The baseline, pre-CBT, mid-CBT and post-CBT 
scores were analyzed between groups with 
single-factor (time) repeated-measures analyses of 
variance (ANOVAs) using Greenhouse–Geisser 
correction. Pairwise differences were measured 
using paired t-tests with Bonferroni correction to 
control for Type I error. The adjusted α value was α 
= .05 / 4 = .013. 
The mean changes in our primary outcome 
measure (LSAS) were calculated among patients 
showing both symptomatic response and remission. 
We established the following threshold for response 
and remission [Bandelow et al., 2006]: 
treatment-responder status was defined as a 
31%-or-greater reduction in LSAS score over the 
course of treatment, and remission was defined as a 
score of ≤ 36 on the LSAS. Moreover, patients who 
met the remission criteria were confirmed to no 
longer meet the criteria for SAD diagnosis using 
SCID-I interviews conducted by a skilled 
psychiatrist who was not a CBT therapist. 
Moreover, the magnitude of the treatment effect 
was determined as the effect size ([Mpre−CBT − 
Mpost−CBT]/SDpre−CBT) for each scale (LSAS, SPS, 
SIAS, FNE, and FQ-SP). According to Cohen 
[Cohen, 1988], effect sizes are categorized as 
follows: small (.20–.49), medium (.50–.79), and 
large (≥ .80). Effect sizes reported in previous 
studies were calculated by different methods for 
various outcome measures. For a direct comparison 
among different CBT studies, we recalculated the 
effect sizes for each study based on these measures 
of SAD severity using the formula ([Mpre−CBT − 
Mpost−CBT]/SDpre−CBT). 
Finally, in order to elucidate the baseline 
predictors of treatment outcomes, multiple 
regression analyses were conducted with 
post-treatment LSAS scores as a dependent variable 
and the baseline demographic and clinical variables 
(gender, age, SAD subtype, presence of comorbid 
major depressive disorder, presence of another 
comorbid anxiety disorder, presence of avoidant 
personality disorder, age of onset, duration of SAD, 
employment status, marital status, educational status, 
use of medication, presence of resistance to 
antidepressants) as independent variables while 
controlling for baseline LSAS scores. 
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3-3. RESULTS 
Treatment acceptability by the therapists 
All of the participating therapists participated in the 
CBT training program (Chiba Improving Access for 
Psychological Therapies project) for 2 years and 
were able to adhere to the treatment protocol under 
weekly supervision. The mean CTS-R rating 
(adjusted for caseload) was 36.1 (on the basis of 15 
randomly selected sessions; average SD = .39), 
which is greater than the threshold of competence 
expected in UK CBT training programs [Blackburn 
et al., 2001]. 
 
Baseline data 
Participants were recruited according to the 
Consolidated Standards of Reporting Trials 
(CONSORT) guidelines, as presented in Figure 2. 
Of the 19 subjects screened, 15 were eligible for the 
study criteria and referred to the study. After 
enrolling in the study, no patient dropped out 
throughout the study. Table 1 shows the baseline 
demographic and clinical variables of the 15 patients 
enrolled in this study. The participants included 12 
women (80%), and the patients’ mean age was 29.9 
years. All participants met the principal DSM-IV 
diagnostic criteria for SAD. Additional Axis I 
diagnoses for the patients included major depressive 
disorder (53%) and other anxiety disorders (e.g., 
panic disorder with agoraphobia; 7%). Other 
demographic and clinical variables of the 
participants are shown in Table 1. 
 
Treatment outcomes 
Table 2 presents the mean baseline, pre-CBT, 
mid-CBT, and post-CBT raw scores for the primary 
and secondary outcome measures. Single-factor 
repeated-measures ANOVAs showed significant 
main effects of time on all outcome measures after 
the completion of treatment (p < .001). Pairwise 
comparisons of outcome measures indicated that the 
completers did not improve on any measure during 
the 2-week waiting period (baseline to pre-CBT); 
this indicates the baseline stability of their 
symptoms. On the other hand, the CBT intervention 
led to significant reductions in all outcome measures 
at the middle stage of treatment (pre–mid-CBT; p 
< .05) and a further significant reduction after 
treatment completion (mid–post -CBT; p < .05). On 
the basis of our primary outcome measure (LSAS), 
11 patients (73.3%) were judged to be responders, 
and 6 of them (40%) met the criteria for SAD 
remission at the post-CBT evaluation. 
As shown in Table 3, our pre–post-CBT effect 
sizes were large and provided comparable 
effectiveness to those obtained in previous studies of 
individual CBT, as determined using the model of 
Clark and Wells for all social-severity scales (effect  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CONSORT participants’ flow 
diagram. Abbreviations: CBT, Cognitive 
Behavioral Therapy. 
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sizes for LSAS = 1.71, SPS = 0.96, SIAS = 1.80, 
FNE = 1.82 and FQ-SP = 1.54). [Table 3] 
 
Predictors of CBT outcomes 
None of the baseline demographic and clinical 
variables (gender, age, SAD subtype, presence of 
comorbid major depressive disorder, presence of 
another comorbid anxiety disorder, presence of 
avoidant personality disorder, age of onset, duration 
of SAD, employment status, marital status, 
educational status, use of medication, and presence 
of resistance to antidepressants) were significant 
predictors of post-treatment LSAS score. 
 
3-4. DISCUSSION 
This single-arm trial demonstrated that individual 
CBT, which was originally developed in Western 
countries, could lead to a significant reduction in 
SAD severity among Japanese patients. Moreover, 
our individual CBT demonstrated excellent 
acceptability, considering that there was no dropout 
among the participants.  
Although the severity of SAD among our 
recruited patients was higher than that observed in 
previous studies (see Table 3), our effect size of 1.71 
in terms of LSAS scores between the pre- and 
post-CBT observations is comparable to the effect 
sizes of 1.29–1.94 reported in previous clinical trials 
on CBT that used the model of Clark and Wells 
[Mörtberg et al., 2007; Stangier et al., 2003; Clark et 
al., 2003; Clark et al., 2006; Stangier et al., 2011]. 
Comparison of effect sizes among various studies 
may be difficult, because the LSAS was 
administered by different methods (self-reported vs. 
clinician-administered) across the different studies. 
However, it is thought to be possible to compare 
these different types of LSAS scores, because scores  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
on the self-report version of the LSAS correspond 
well to those on the clinician-administered version: 
In a previous study group, there was little difference 
between the two versions of the LSAS on any scale 
or subscale score [Fresco et al., 2001]. 
Our identification of possible predictors of 
response to CBT showed that the observed baseline  
Table 1. Baseline demographic and clinical 
characteristics(N = 15) 
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demographic and clinical variables were not 
statistically significant predictors of LSAS scores 
after receiving CBT. The presence of comorbid 
mood disorders did not predict CBT outcomes in 
this study, and some previous studies have also 
demonstrated that individuals with comorbid mood 
disorders responded similarly to those with 
uncomplicated SAD [Marom et al., 2009; 
Chambless et al., 1997]. However, Blanco (2003b) 
found pretreatment levels of self-reported 
depression to be the single most significant predictor 
of treatment outcomes. Thus, it may be necessary to 
assess the level of severity of comorbid depression 
to facilitate the prediction of CBT outcomes in 
further studies. As for antidepressant history, it is 
reported that about 50% of individuals do not 
respond to antidepressants or have residual  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
symptoms after first-line antidepressant treatment 
[Van Ameringen et al., 2004]. Most patients (73%) 
who participated in the current study showed 
resistance to first-line medications (at least one 
course of SSRI administration at the maximum dose 
for at least 12 weeks). One reason for this pattern of 
results is that only SSRIs (fluvoxamine and 
paroxetine) have been approved as treatments for 
SAD in Japan as of 2012. However, in the present 
study, CBT decreased SAD severity similarly in 
antidepressant resistant patients and 
antidepressant-responsive ones (i.e., the presence of 
antidepressant resistance was not a predictor of CBT 
outcomes). This finding suggested that individual 
CBT might have potential as a next-step strategy 
even for cases of antidepressant-resistant SAD. 
Though the present study provided valuable  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Comparison of effect sizes among various clinical trials using the model of Clark 
and Wells 
Table 2. Repeated-measures analyses of variance (N = 15) 
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information, its design imposes the following 
limitations. (1) This study included only a small 
sample size, which resulted in limited 
generalizability of its conclusions. (2) This was a 
single-center study; therefore, our participating 
population was somewhat different from those seen 
in routine clinical practice. Our study was designed 
to recruit patients similar to those seen in routine 
clinical practice; as a result, 40% had comorbid 
disorders, as is typical in clinical practice [Stein, 
2008]. However, although the gender ratio of SAD 
cases is not typically skewed, the participants in this 
study were mostly women. The reason for this was 
that our outpatient section always took appointments 
during the daytime on weekdays; therefore, many 
men who worked weekdays could not participate in 
this study. (3) The lack of follow-up data limits the 
generalizability of the study’s conclusions to 
longer-term outcomes. This is an important 
consideration in evaluating the effectiveness of CBT, 
because CBT has unknown characteristics in terms 
of longer-term effects, associated relapse rates, cost 
effectiveness characteristics, etc. (4) Psychotropic 
medication intake could not be discontinued before 
the start of this study. Though the inclusion of 
subjects using psychotropic medication limits the 
generalizability of the results, most patients (73%) 
already showed resistance to first-line medications 
(such as SSRIs) at baseline, and all of the patients 
showed baseline stability of their symptoms during 
the 2-week waiting period. Thus, it seemed that our 
individual CBT did indeed reduce SAD severity. (5) 
This was an uncontrolled study; therefore, we could 
not conclude definitively that our individual CBT 
was effective. It remains unknown whether the 
observed improvement in SAD severity is related to 
the natural course of SAD. 
Future study should replicate these findings and 
address the limitations of this study in multi-center, 
randomized, controlled trials conducted with larger 
and more diverse samples across longer follow-up 
periods. 
Despite several limitations, this study suggests via 
a single-arm design that individual CBT is a feasible 
treatment, even for Japanese patients with SAD. 
Further controlled trials that address the limitations 
of this study are required. 
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4. Strategy for treating selective serotonin 
reuptake inhibitor resistant social anxiety 
disorder in the clinical setting: a 
randomized controlled trial protocol of 
cognitive behavioral therapy in 
combination with conventional treatment 
 
4-1. BACKGROUND 
Introduction 
As of 2012, though empirically derived treatment 
algorithms for SAD do not exist, pharmacotherapy 
and CBT have consistently been shown to be 
effective as first-line treatments in a large database 
of randomized controlled trials, and are 
recommended in many countries [Fedoroff & Taylor, 
2001; Stein et al., 2004]. The following summary is 
based on the primary literature, meta-analyses, 
systematic reviews, ongoing clinical experience, 
published guidelines and the current status of 
treatment in clinical practice [Bandelow et al., 2008; 
Baldwin et al., 2005; Swinson et al., 2006; Stein et 
al., 2010a]. 
 
First-line CBT 
CBT has consistently been shown to be effective as 
first line treatments in randomized controlled trials 
[Fedoroff & Taylor, 2001]. There are basically three 
types of CBT: individual CBT, group CBT and 
internet CBT. Recent studies have demonstrated the 
superiority of individual format CBT over group 
format [Mörtberg et al., 2007; Stangier et al., 2003], 
and internet CBT has shown comparable 
effectiveness to group CBT [Hedman et al., 2011]. 
While no clear evidence has shown that the 
combination of SSRIs and CBT is more effective 
than single-modality treatment [Blomhoff et al., 
2001; Davidson et al., 2004]. CBT has a number of 
potential advantages over pharmacotherapy in the 
treatment of anxiety disorder (including individual 
-based, group -based and internet-based): longer 
effects, fewer adverse effects, smaller relapse rates 
and greater acceptability [Gelernter et al., 1991; 
Heimberg et al., 1998; Hofmann et al., 1998; 
Hedman et al., 2012]. Pharmacotherapy has 
disadvantages such as more side effects and higher 
rates of relapse with the discontinuation of 
medication [Lepola et al., 2004; Liebowitz et al., 
2005], and patients often prefer psychological 
treatment (even if this is more well known in the 
depression literature) [Dwight-Johnson et al., 2000]. 
Nevertheless, CBT is used much less frequently 
in clinical practice because of the limited 
availability of specialized practitioners and it has 
received much less promotion from pharmaceutical 
companies than pharmacotherapy [Insel, 2009]. 
Thus, pharmacotherapy is actually used as a first 
choice treatment for SAD by most clinicians, even 
in countries with initiatives to improve access to 
psychological therapies (e.g. the UK, Australia) 
[Department of Health, 2011a & b; Pirkis et al., 
2004]. 
 
First-line pharmacotherapy 
With regard to pharmacotherapy, treatment varies 
according to the subtypes (generalized and 
non-generalized). However, we focus primarily on 
treatment options for generalized SAD because 
currently there is very limited clinical trial-based 
evidence for the treatment of non-generalized SAD 
[Liebowitz et al., 1992; Davidson et al.,1993]. 
Pharmacotherapy, as a first-line treatment for SAD, 
currently involves the use of SSRIs. A growing 
database of randomized controlled trials had 
demonstrated that SSRIs are effective and well 
tolerated [Stein et al., 2004; Blanco et al., 2003a; 
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Ipser et al., 2006]. Further, there is strong evidence 
that SSRIs are also effective for treating many of the 
comorbid conditions, such as depression and other 
anxiety disorders, frequently associated with SAD. 
Serotonin-noradrenalin reuptake inhibitors are 
also recommended for first-line pharmacotherapy. 
However, there are comparatively few studies on 
this class of drugs, in comparison with SSRIs, and 
only venlafaxine has been demonstrated to be 
effective [Liebowitz et al., 2005a & b; Stein et al., 
2005a]; therefore, fewer countries have approved 
serotonin-noradrenalin reuptake inhibitors for 
treating SAD than SSRIs (e.g. they have not been 
approved in Japan). 
SSRIs have a relatively flat dose–response curve 
[van der Linden et al., 2000]. Nevertheless, evidence 
suggests that a superior response may be obtained 
with higher doses of SSRIs.[35] Clinical experience 
also suggests that some patients may require higher 
than normal starting doses to achieve an optimal 
response, and may even require maximal doses. 
SSRI administration should last for at least 12 weeks 
before its efficacy is assessed [Stein et al., 2002]. Of 
course, SSRI treatment usually includes some type 
of non-specific psychotherapy (e.g. supportive 
counseling) from the general practitioner. 
 
Second-line treatment options for SSRI 
resistant SAD cases 
A significant proportion of SAD patients fail to 
respond to initial treatment with SSRIs [Stein & 
Stein, 2008]. The presence of residual symptoms is 
known to be associated with higher relapse rates, 
decreased quality of life and greater functional 
impairment [Fava & Tomba, 2009]; however, there 
is no standard approach to their management. On the 
whole, conventional second-line treatment is based 
on the clinician’s own judgment. Clearly, it is of 
increasing importance to consider therapeutic 
alternatives for patients with SAD who demonstrate 
resistance to SSRIs. A systematic review has 
advocated reviewing treatment options with limited 
evidence, including augmentation with another 
pharmacological agent or switching to another 
antidepressant, if patients show little or no response 
to the initial SSRI treatment after 12 weeks [Stein et 
al., 2002]. 
Limited evidence supports the value of 
augmenting SSRI treatment with buspirone [Van 
Ameringen et al., 1996], clonazepam [Seedat & 
Stein, 2004] and atypical antipsychotic medications, 
such as risperidone and aripiprazole.[ Simon et al., 
2006; Worthington et al., 2005] A few studies have 
shown positive results when treatment was switched 
to a second SSRI or to a serotonin-noradrenalin 
reuptake inhibitor in SAD patients who failed to 
respond to initial SSRI treatment [Pallanti & 
Quercioli, 2006; Kelsey, 1995; Altamura et al., 
1999]. 
 
CBT as a second-line treatment for SSRI 
resistant SAD cases 
While there is some evidence of the effectiveness of 
combined pharmacotherapy and CBT, the evidence 
for an additive effect when combining the two 
modalities is mixed; further, there is no evidence 
concerning the effectiveness of combined therapy 
specific to SSRI-resistant cases [Blomhoff et al., 
2001; Davidson et al., 2004; Blanco et al., 2010] 
Previously published systematic reviews, including 
case reports with ≥11 cases are not available 
regarding the use of CBT as a next step for SSRI 
non-remitters among SAD patients [ Rodrigues et al., 
2011]. In our preliminary study [Yoshinaga et al., 
2013], most patients with SAD exhibited substantial 
resistance to SSRIs; however, 73% of the 
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participants in the study were judged to be treatment 
responders, with 40% meeting the criteria for 
remission. The within-group effect size, between pre 
and post-CBT, on the Liebowitz Social Anxiety 
Scale (LSAS) total score was also large (Cohen’s 
d=1.71). Thus, this preliminary study suggested that 
CBT might have potential as a next-step strategy, 
even for cases of SSRI-resistant SAD. 
 
Aims 
In summary, this paper describes the study protocol 
for a randomized controlled trial to evaluate the 
clinical effectiveness of CBT administered 
concomitantly with conventional treatment for 
patients with SSRI-resistant SAD. 
 
4-2. METHODS 
Study design 
A randomized controlled trial design employing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
psychological placebo conditions with 
single-blinded for patients to control non-specific 
factors (e.g. time of contact between the patient and 
therapist, patient’s expectations of a particular 
therapy, reasonable rationale for intervention and 
discussions of the psychological problem) is the 
most desirable trial design for verifying the 
effectiveness of psychological interventions 
[Hofmann & Smits, 2008]. However, a 
psychological placebo differs from a pill placebo in 
that patient blinding is extremely difficult and is 
neither feasible nor practical in the former case; thus, 
placebo control conditions cannot control the 
patient’s expectations from CBT. A psychological 
control condition, which is not single-blinded for 
patients, may be employed to control the time of 
contact (e.g. relaxation training or supportive 
psychotherapy to be presented to share the same 
duration as the CBT); however, such methods are 
vastly different from conventional treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Patient flow during 
inclusion, randomization and 
treatment. 
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For the reasons listed above, this study was 
designed as a Prospective Randomized Open 
Blinded End-point trial with two parallel groups and 
with dynamic allocation at the individual level. 
Further, the intervention groups consist of a 16-week 
treatment regime of conventional treatment, alone, 
and a CBT program combined with conventional 
treatment (see figure 3). 
 
Participants 
Inclusion criteria 
The inclusion criteria for this study include a 
primary diagnosis of SAD, according to the 
Diagnostic & Statistical Manual for Mental 
Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) [American Psychiatric Association, 
2000]; patients between 18 and 65 years, SAD of at 
least moderate severity, based on an LSAS score 
≥50 [Liebowitz, 1987], and defined as resistant to 
SSRIs, with at least one SSRI found to be 
inadequate for treatment despite administration at 
the maximum dose for at least 12 weeks, or 
intolerance to SSRIs (e.g. because of drowsiness, 
nausea, sleep disturbances, sexual dysfunction and 
appetite change). In order that the study population 
reflects routine clinical practice [Simon et al., 2004; 
Rush et al., 2005; Beesdo et al., 2007], comorbid 
diagnoses will be permitted if they are clearly 
secondary (i.e. SAD symptoms are both the most 
severe and the most impairing). 
 
Exclusion criteria 
The exclusion criteria for this study include 
psychosis, pervasive developmental disorders 
/mental retardation, autism spectrum disorders, 
current high risk of suicide, substance abuse or 
dependence within the 6 months prior to enrolment, 
antisocial personality disorder, unstable medical 
condition, pregnancy or lactation. In addition, much 
to very much improvement resulting from some type 
of treatment within 12 weeks prior to the study, as 
ascertained by a Clinical Global Impression 
Improvement scale score of ≤ 2 [Guy, 1976], as 
reported by the patient and confirmed by the 
prescribing clinician, when possible, will also be 
sufficient to exclude the patient from the trial. 
 
Eligibility procedure for participation and 
diagnosis 
All patients will be evaluated by a psychiatrist and a 
study investigator using the Structured Clinical 
Interview for Axis I Disorders (SCID-I) [First & 
Gibbon, 1997a] and SCID-II [First & Gibbon, 
1997b]. Treatment history will be confirmed by the 
prescribing clinician and by chart review. 
Eligibility for participation in this clinical trial 
will be determined with the aid of a three-step 
procedure. First, the diagnosis and eligibility for 
participation will be checked by both a psychiatrist 
and a study investigator. Second, the validity of the 
initial diagnosis and eligibility will be discussed at a 
general meeting, to include psychiatrists, nurses, 
clinical psychologists and psychiatric social workers. 
Third, patients will be re-evaluated to cover 
important missing information, based on the 
suggestions derived from the second step, and the 
final diagnosis and eligibility will be confirmed by 
both a psychiatrist and a study investigator. 
 
Recruitment 
The planned recruitment rate is two participants per 
month, between May 2012 and March 2014, or until 
a total of 42 participants have been recruited. 
Participants will be recruited through posters and 
leaflets placed at medical institutions in Chiba 
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Prefecture and through web-based and newspaper 
advertisements. As all participants will continue to 
be treated by their general practitioners, the patients 
will be required to obtain permission from their 
general practitioner prior to study enrolment. 
 
Interventions 
Conventional treatment 
There are no restrictions on treatment options for 
patients who receive treatments, naturally including 
medication change, from their general practitioners. 
General practitioners will be permitted to refer 
patients for counseling or to secondary care if this is 
deemed clinically appropriate. However, the 
initiation of a strictly structured CBT program is 
banned in order to properly assess the effectiveness 
of the CBT intervention. All changes in 
conventional treatment, with the reasons for these 
changes, will be recorded throughout the study 
period. 
 
CBT program 
Individual-administered CBT will be employed in 
this study. CBT intervention will be conducted over 
16 weekly, individual sessions. Most sessions will 
last for a period of 50 min, but the protocol allows 
therapists to extend up to six sessions to a maximum 
of 90 min to facilitate behavioral experiments. The 
CBT program is based on that of Clark and Wells 
[Heimberg, 1995] because this CBT model has 
demonstrated excellent treatment outcomes 
[Mörtberg et al., 2007; Stangier et al., 2003 & 2011; 
Clark et al., 2003 & 2006] The main parts of this 
protocol include: (1) developing an individualized 
version of the cognitive-behavioral model of SAD, 
(2) conducting role play-based behavioral 
experiments, with and without safety behaviors, (3) 
restructuring distorted self-imagery using videotape 
feedback, (4) practicing external focus and shifting 
attention, (5) performing a behavioral experiment to 
test the patient’s negative beliefs, (6) modifying 
problematic pre-event and post-event processing, (7) 
surveying the differences between the beliefs of self 
and those of others, (8) dealing with the remaining 
assumptions (schema work), (9) rescripting early 
memories linked to negative images in social 
situations and (10) preventing relapse. Participants 
will be assigned homework after every session. 
Moreover, therapists will be allowed to customize 
the CBT program, over the remaining sessions, in 
order to suit individual requirements, based on the 
symptoms and intelligibility (i.e. another behavioral 
experiment, a review session to improve 
understanding and discussion of rigid dysfunctional 
schema). Further, therapists will be allowed to 
further customize the sessions at any stage of the 
CBT program. 
 
Therapist and quality control 
CBT will be delivered by therapists (psychiatrists, 
nurses, clinical psychologists and psychiatric social 
workers) experienced in the use of the CBT program 
for patients with SAD, and by those who have 
already received the CBT training program at Chiba 
University (Chiba Improving Access for 
Psychological Therapies project). To assist with 
planning future sessions, all therapists will attend 
weekly group-supervision sessions with other 
therapists and individual-supervision sessions with a 
senior supervisor throughout the study period. 
Senior supervisors will also assess the general 
quality of each CBT program on the basis of the 
revised Cognitive Therapy Scale-Revised 
[Blackburn et al., 2001], by reviewing randomly 
selected, video-taped sessions. Study investigators 
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will check the therapists’ protocol adherence and the 
homework adherence by patients using the original 
checklist. 
 
Outcomes 
Baseline and clinical characteristics 
Baseline characteristics will include sex, age, 
education, marital status, employment status, age at 
SAD onset, duration of SAD and axis I 
comorbidities. Moreover, the treatment history will 
include the names of the SSRIs to which the 
participant has exhibited resistance, other prior 
treatments, current treatment (medication and 
others) at baseline and all changes in conventional 
treatment throughout the study period. 
 
Primary outcome 
The primary outcome will be clinician-determined 
symptoms of social anxiety, as measured on the 
LSAS [Liebowitz, 1987], which is the most 
commonly used scale for assessing the SAD severity 
[Heimberg et al., 1999]. 
 
Secondary outcomes 
The secondary self-reported outcomes will be 
determined using the Social Phobia and Anxiety 
Inventory [Turner et al., 1989], Beck Depression 
Inventory-II [Beck et al., 1997], Sheehan Disability 
Scale [Leon et al., 1997], WHO Quality of 
Life-Brief version [Skevington et al., 2004] and the 
EuroQol-5 Dimensions [EuroQol group, 1990]. 
Moreover, the Clinical Global Impression 
Scale-Severity of Illness and Improvement [Zaider 
et al., 2003] will be rated by an independent 
assessor. 
 
Blinding and quality control for the independent 
assessor 
Treatment outcomes will be assessed by two 
independent assessors and the end-point committee 
who have no other contact with the study 
participants, to prevent identification of the 
treatment assignments. Further, participants will be 
instructed to not tell the assessor about their 
treatment assignment prior to the assessment. 
Independent assessors will receive training and 
supervision by the study investigator as well as a 
manual outlining the procedures for each 
clinician-administrated measure. The independent 
assessors will meet to review these procedures by 
the study investigator. 
 
Sample size 
Forty-two patients will be randomized into the study. 
This sample size was based on results from our 
previous pilot study that indicated that the estimated 
group difference in LSAS scores was approximately 
30. The conventional treatment alone is assumed to 
be largely ineffective. Assuming a group difference 
of 30 points (SD=30), 18 subjects per arm will 
provide >80% power to detect a difference in LSAS 
scores between the conventional treatment arm and 
the arm with CBT combined with conventional 
treatment for at least 16 weeks, using a two-sided, 
two-sample t test at a 5% level of significance. Thus, 
allowing for a 20% dropout rate, 21 participants are 
required per group, for a total of 42 patients in the 
study. 
 
Randomization 
At the end of the baseline assessment, the eligible 
patients will be randomly assigned to either the 
conventional treatment arm or CBT combined with 
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the conventional treatment arm at a ratio of 1:1, with 
the assignments made at the data center (the Clinical 
Research Centre, Chiba University Hospital) by 
means of the minimization method [Brown et al., 
2005], ensuring a balance in baseline LSAS scores 
(LSAS ≥70, or less), gender and current treatment 
with SSRIs (yes or no). 
The study investigator will review the 
randomization online, and the participant will then 
be provided with an appointment to undergo one of 
the two treatment regimes. The patient will be 
blinded to the group to which they are assigned 
before they consent to participate in the study. 
 
Statistical analysis 
Statistical analysis and reporting of this trial will be 
conducted in accordance with CONSORT guidelines, 
with the primary analyses based on the 
intent-to-treat principle without imputing missing 
observations. As a sensitivity analysis, the multiple 
imputation method will be applied to examine the 
effect of missing data. For the baseline variables, 
summary statistics are constructed employing 
frequencies and proportions for categorical data, and 
mean and SD for continuous variables. The baseline 
variables are compared using Fisher’s exact test for 
categorical outcomes and unpaired t test for 
continuous variables, as appropriate. 
For the primary analysis to compare treatment 
effect, the least squares means (LSMean) and their 
95% CI, which are estimated by using analysis of 
covariance (ANCOVA) with LSAS total scores 
(untransformed) on week 16, were compared 
between treatments (the conventional treatment 
alone vs CBT combined with conventional 
treatment) using an ANCOVA model, taking into 
account the variation due to treatment effects, and 
using the baseline LSAS score (LSAS ≥70, or less), 
gender and current treatment with SSRIs as the 
covariate. The LSMean is calculated for each 
treatment. To compare the treatment groups, the 
difference in LSMeans and the associated 95% CI 
are expressed as a proportion of the reference 
treatment LSMean. As a sensitivity analysis, the 
outcomes at weeks 0, 8 and 16 are modeled as a 
function of time, treatment and treatment-by-time 
interaction using linear mixed-effects models. 
Secondary outcomes are scores on the Social Phobia 
and Anxiety Inventory, Beck Depression 
Inventory-II, Sheehan Disability Scale, WHO 
Quality of Life-Brief version, EuroQol-5 
Dimensions, the Clinical Global Impression 
Scale-Severity of Illness and Improvement and rates 
of the responder (defined as a reduction of 31% or a 
greater reduction in the LSAS score over the course 
of treatment duration) and of remission (defined as a 
score of 36 or less on the final LSAS score and no 
longer diagnosed with SAD by the DSM-IV-TR) 
[Bandelow et al., 2006]. The secondary analysis is 
performed in the same manner as the primary 
analysis. 
All p values calculated in the subgroup analysis 
are two-sided and are not adjusted for multiple 
testing. p Values of less than 0.05 are considered to 
indicate statistical significance. 
 
4-3. ETHICS AND DISSEMINATION 
This study will be conducted at the Academic 
Outpatient Clinic of Chiba University. The study 
protocol has been approved by the Institutional 
Review Board of the Chiba University Hospital 
(Reference number: G23075). The trial is registered 
as UMIN000007552. 
When the potential participant contacts the study 
trial office, he or she will be informed of the 
objectives of the study and asked if they are willing 
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to participate. Each patient will be informed that 
participation is voluntary and that full anonymity 
will be provided to each participant. Each person 
will then be required to provide written informed 
consent for their participation in this study. Each 
patient will also be informed that all of the 
participants will receive conventional treatment 
from their general practitioner; half of the recruited 
individuals will also receive CBT, in addition to 
their conventional treatment. A doctor’s examination 
at each assessment point (at weeks 0, 8 and 16) and 
blood withdrawn before and after the intervention 
will be performed for the evaluation of adverse 
events. An adverse event can be any unfavorable 
and unintended sign, symptom or disease temporally 
associated with this interventional study, whether or 
not considered related to this CBT, and all adverse 
events will be reported. Serious adverse events 
would be immediately reported to this committee as 
well as registered through the hospital risk 
management system. Furthermore, an independent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
progress of the clinical trial, the safety data and 
critical efficacy variables and provide 
recommendations to the sponsor regarding the 
continuation, modification or termination of the 
trial. 
The results of the trial will be published in 
appropriate journals, regardless of the outcomes. 
The trial will be implemented and reported in 
accordance with the recommendations of 
CONSORT. 
 
4-4. CURRENT STUDY STATUS 
The study began recruiting patients in May 2012 and 
recruitment will be closed at the end of December 
2013. The number of final registered patients was 26 
as of March 2013 (see figure 4). 
 
4-5. DISCUSSION 
This study is designed to address the lack of 
research on the use of CBT in combination with the 
conventional treatment of SSRI-resistant SAD, and 
Figure 4. Current progress of the registered patients as of March 2013. 
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is expected to have sufficient power to detect a 
meaningful difference in outcomes. Moreover, the 
findings of this study will provide valuable evidence 
to help develop second-line treatments and establish 
treatment algorithms. The limitation of this study is 
that the specific effects of the CBT program, based 
on Clark and Wells (including the videotape 
feedback and behavioral experiment sessions), 
cannot be revealed because a psychosocial 
comparison group will not be employed in this 
study. 
 
Patient consent Written informed consent was 
obtained from the patient for publication of this 
report and any accompanying images.  
Competing interests The authors declare that they 
have no competing interests.  
Ethics approval and trial registration This study 
will be conducted at the academic outpatient clinic 
of Chiba University Hospital. Ethics approval was 
granted by the Institutional Review Board of Chiba 
University Hospital (Reference number: G23075), 
and was registered in the national UMIN Clinical 
Trials Registry (ID: UMIN000007552).  
Funding The primary sources for funding for this 
project are grants from Grant-in-Aid for Scientific 
Research from the Japanese Ministry of Health, 
Labor and Welfare (MHLW) (22SE1P0051). The 
MHLW plays no role in the collection, management, 
analysis and interpretation of data, and will not have 
any impact on the trial and the publication of the 
results. 
 
 
 
 
5. General Discussion and Conclusion 
The single-arm trial demonstrated that individual 
CBT, which was originally developed in Western 
countries, could lead to a significant reduction in 
SAD severity among Japanese patients. Moreover, 
our individual CBT demonstrated excellent 
acceptability, considering that there was no dropout 
among the participants. And, the single-arm study 
also suggested that individual CBT might have 
potential as a next-step strategy even for cases of 
antidepressant-resistant SAD. 
In addition, our ongoing RCT is the first trial to 
focus on CBT as a therapeutic option for 
SSRI-resistant SAD patients. This RCT reflects 
good clinical practice, and its results will contribute 
to the development of second-line treatments and 
establish future treatment algorithms. 
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